Shengshi Junlian Secures Tens of Millions RMB in Series A Funding Led by Gaoxin Venture Capital to Accelerate Commercialization of AI-Driven 300-Billion-Diversity Biologics Library

Recently,ABLINK Biotechnology Co., Ltd. announced the completion of an angel round of financing worth tens of millions of RMB and on October 17thAt the 2025 China Chengdu Angel Investment Ecosystem Conference with the Lead Investor HTVEOfficially Completed Investment Signing. This round of financing will be used to accelerate the company's upgrade of the AI + large molecule innovative drug development technology platform and commercialization layout.

HTVE, a wholly-owned subsidiary of Chengdu High-Tech Science and Technology Innovation Investment Development Group Co., Ltd., has cumulatively invested in more than 150 angel and startup projects over the years, helping over 35 invested companies go public on China's SME Board, Growth Enterprise Market (GEM), STAR Market, Hong Kong Main Board, and the New Third Board. In 2015, the company was ranked among the "Top 50 Local Venture Capital Institutions in China 2015" by Zero2IPO Group. In 2016, it was listed as one of the "Top 100 Venture Capital Institutions in China 2016" by Zero2IPO Group, being the only venture capital institution in Sichuan to receive this honor. In January 2018, the company was awarded the "Best Early-Stage Investment Fund in China 2017" by the Zhongguancun Equity Investment Association in collaboration with over 20 provincial equity investment associations across China. In December 2019, the company was recognized as one of the "Top 50 State-Owned Investment Institutions in China 2019" by Zero2IPO Group. In January 2020, it was named the 2019 "Jingrong Venture Capital Star" by the Chengdu Science and Technology Bureau. In 2023, the company received several industry accolades, including Zero2IPO's "Top 30 District/County Government Guidance Funds in China 2023," ChinaVenture's "Top 30 Best Venture Capital Guidance Funds in China 2023," ChinaVenture's "Most GP-Focused Government Guidance Fund in China 2023," the Private Equity Fund Research Center's "Top 3 Best Angel Mother Funds 2023," the Private Equity Fund Research Center's "Top 27 Best Risk Control District/County Government Guidance Funds 2023," and the Private Equity Weekly's "Top 20 District/County Mother Funds in the 2023 Investment Institution Soft Power Rankings."

ABLINK was founded in 2016 and is committed to the development and project transfer of large molecule innovative drugs, based onGlobal leading 100% multi-site mutation efficiency and directional mutation control full-synthesis library technologyBuilt a 300 billion biopharmaceutical authentic synthesis library with independent intellectual property rights and an AI-assisted drug development platform (ABLINK).^®BioAI for Scientists), capable of providing customers with more efficient one-stop development services for large-molecule innovative drugs, including the discovery, screening, optimization, engineering, and preclinical scientific research of biologics. Several PCC large molecules independently developed by the company have also entered the mature project licensing and transfer stage.

After 9 years of technological breakthroughs and commercial practice, ABLINK's fully synthetic library technology, which achieves 100% multi-site mutation and directed mutation control, has reached a globally leading position in the industry. This is a technical approach that performs high-throughput mutations on multiple sites simultaneously and is commonly used in antibody library synthesis. In this process, it is typically necessary to simultaneously mutate 3 to 6 of the 6 CDR regions of an antibody to ensure sufficient diversity for obtaining highly druggable antibodies. This technology was initially developed by Genentech, and the ABLINK scientific team achieved two decisive technological breakthroughs based on it. The first breakthrough increased single-site mutation efficiency from 60% to 100%, and the second breakthrough achieved 100% multi-site mutation. After these two technological advancements, the efficiency of library construction and the diversity of the libraries were greatly enhanced. Currently, in terms of library construction efficiency, ABLINK can build a synthetic library of 10^11 within just 2 weeks, whereas traditional methods often require more than 3 months. In terms of library quality and screening quality, the 100% multi-site mutation technology ensures that the constructed library perfectly matches the design requirements, truly achieving "what you see is what you get."

By the end of 2024, ABLINK has completed a total ofMore than 300 CRO services for innovative antibody drug development，Drug screening success rate as high as 95%, during which several high-difficulty antibody discovery and modification projects were completed. Clients include leading domestic and international pharmaceutical companies and institutions such as Hengrui, Junshi, Shanghai Pharmaceuticals, Huahai, Entropy Bio, Taiwan Apexigen, Shenzhen Bay Lab, and Tongyuan Kang Bio. Among these, 20+ service projects have entered the clinical stage, over 10 projects have been licensed for transfer, and multiple collaborative projects have achieved milestone results.

Dr. Liu Jianghai, founder and chairman of ABLINK, stated: "We are highly honored to receive recognition and support from HTVE. ABLINK will fully utilize this round of financing to accelerate the upgrade and commercialization of its AI + large molecule innovative drug technology platform, addressing the challenge faced by global biopharmaceutical companies in the development of innovative drugs—‘a fortune is easily obtained, but a capable leader is hard to find.’ We believe that the key to original innovation must return to molecular innovation itself. Identifying a high-potential molecule will greatly expedite clinical translation. However, the chemical space of molecules is vast like an immense ocean, and traditional technologies alone cannot achieve efficient translation. Therefore, we need AI tools to help us more efficiently uncover hidden gold mines. In the future, ABLINK will continue to explore and make breakthroughs in AI + large molecule synthetic library technology, accelerating the journey of innovative drugs from the lab to the market and addressing unmet clinical medication needs."

Huang Chen, founder and general manager of ABLINK, pointed out: "ABLINK is the only company in China that masters the globally leading large-molecule full synthesis library technology, and the only company with the automatic production capacity of massive tagged data. In the future, we are committed to combining our unique massive self-tagged data with AI technology for innovative purposes.By adopting a continuously iterative model that alternates between dry and wet lab approaches, we develop differentiated AI-driven drug discovery models and implement best practices for AI applications. We create ready-to-use AI research tools tailored to specific drug discovery scenarios, such as the AI tool for antibody humanization. Multiple commercial cases have demonstrated that AI can complete calculations within 24 hours, achieving a humanization rate higher than 95%, or even up to 100%, with affinity potentially surpassing that of the parent sequence. In contrast, traditional methods require more than 12 weeks and deliver relatively lower levels of humanization and affinity. This AI tool has already been commercially validated by several clients, including Tasly, Sinopharm East China, Shenzhen Bay, and Huahai. Currently, our AI-driven drug discovery efforts have completed the construction of six major platforms: Virtual Library Screening Platform, De Novo Molecular Design Platform, Multi-Antibody Design Platform, Drug-Likeness Prediction and Optimization Platform, Antibody Data Fusion Platform, and AI Tool Integration Platform. Moving forward, we will use this round of financing to continue innovating and optimizing our technology platforms while building an even more comprehensive system to empower biopharmaceutical technology companies globally.